About VivaChek
VivaChek is a company based in Hangzhou (China) founded in 2013. It operates as a Direct-to-Consumer (D2C) and HealthTech. VivaChek has raised $14.21 million across 1 funding round from investors including UMC Capital. VivaChek offers products and services including VivaChek Blood Glucose Meter, VivaChek Uric Acid Analyzer, and VivaChek COVID Antigen Test Kit.
- Headquarter Hangzhou, China
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name 杭州微策生物技术股份有限公司
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$14.21 M (USD)
in 1 rounds
-
Latest Funding Round
$14.21 M (USD), Series C
Dec 10, 2019
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of VivaChek
VivaChek offers a comprehensive portfolio of products and services, including VivaChek Blood Glucose Meter, VivaChek Uric Acid Analyzer, and VivaChek COVID Antigen Test Kit.
Blood glucose levels are monitored using this device.
Uric acid levels are measured with this analyzer.
COVID-19 antigens are detected using this test kit.
Funding Insights of VivaChek
VivaChek has successfully raised a total of $14.21M through 1 strategic funding round. The most recent funding activity was a Series C round of $14.21 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series C — $14.2M
-
First Round
First Round
(10 Dec 2019)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2019 | Amount | Series C - VivaChek | Valuation | UMC Capital |
|
Investors in VivaChek
VivaChek has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include UMC Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Semiconductors and diverse sectors are targeted by corporate-backed VC investments.
|
Founded Year | Domain | Location |
Investments & Acquisitions by VivaChek
Financial Statements - VivaChek
Vivachek Comparisons
Competitors of VivaChek
Latest news on Vivachek
Frequently Asked Questions about VivaChek
VivaChek was founded in 2013 and raised its 1st funding round 6 years after it was founded.
VivaChek is headquartered in Hangzhou, China. It is registered at Hangzhou, Zhejiang, China.
VivaChek is a funded company, having raised a total of $14.21M across 1 funding round to date. The company's 1st funding round was a Series C of $14.21M, raised on Dec 10, 2019.
VivaChek, based in Hangzhou, China, is focused on the research, development, production, and sales of point-of-care testing (POCT) products. The company is dedicated to building an ecosystem of chronic disease management, rapid diagnostics, and digital healthcare. Solutions are provided in sectors such as blood glucose monitoring, uric acid analysis, and infectious disease detection. The aim is to become a globally trusted provider of smart POCT solutions, making health management accessible to all.
VivaChek offers VivaChek Blood Glucose Meter, VivaChek Uric Acid Analyzer, and VivaChek COVID Antigen Test Kit.
VivaChek has 1 investor. Key investors include UMC Capital.